STERIS plc (STE) is attracting renewed analyst confidence after strong Q3 FY2026 financial results. Citizens reiterated its “Market Outperform” rating with a $280 price target, following STERIS beating revenue expectations and matching profit forecasts. The company’s organic revenue growth and reaffirmed full-year guidance suggest a robust position in the medical technology sector, despite expected tariff impacts.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
STERIS plc (STE) Remains in Focus as Analysts Reaffirm Confidence
STERIS plc (STE) is attracting renewed analyst confidence after strong Q3 FY2026 financial results. Citizens reiterated its “Market Outperform” rating with a $280 price target, following STERIS beating revenue expectations and matching profit forecasts. The company’s organic revenue growth and reaffirmed full-year guidance suggest a robust position in the medical technology sector, despite expected tariff impacts.